Doximity price target lowered to $19 from $29 at Truist

Truist analyst Jailendra Singh lowered the firm’s price target on Doximity (DOCS) to $19 from $29 and keeps a Hold rating on the shares after the company’s Q1 results and worse than expected 2027 outlook. Doximity has now transitioned from a clear growth leader to a more mature, challenged platform with rising risk of incremental share erosion, the analyst tells investors in a research note. Truist adds that for many health care IT companies, when revenue growth visibility diminishes and competitive pressure intensifies, valuations can remain depressed for a prolonged period.